Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer
This is a single-arm, exploratory study to evaluate the efficacy and safety of HAIC in combination with surufatinib and tislelizumab in the first line treatment of patients with unresectable or metastatic biliary tract cancer
Carcinoma|Intrahepatic Cholangiocarcinoma|Gallbladder Cancer|Surufatinib|Angiogenesis Inhibitors|Tislelizumab|Antineoplastic Agents, Immunological|Immunotherapy
DRUG: HAIC|DRUG: Surufatinib|DRUG: Tislelizumab
Progress free survival (PFS) per RECIST v1.1, Defined as a duration from the date of initial treatment to disease progression or death of any cause, From baseline to primary completion date, about 18 months
Overall response rate (ORR) per RECIST v1.1 and mRECIST, Defined as the sum of the complete response and partial response rate, From baseline to primary completion date, about 3 months|Disease control rate (DCR) per RECIST v1.1 and mRECIST, Defined as the sum of the complete response, partial response and stable disease, From baseline to primary completion date, about 3 months|Overall survival (OS), Defined as a duration from the date of initial treatment to death of any cause, From baseline to primary completion date, about 24 months|Conversion to surgical resection rate, Defined as the proportion of patients who were successfully converted to radical resection with negative hepatic margins after the study treatment regimen was calculated, From baseline to primary completion date, about 6 months|Incidence rate of adverse events, Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0, From baseline to primary completion date, about 18 months
This is a single-arm, exploratory study to evaluate the efficacy and safety of HAIC in combination with surufatinib and tislelizumab in the first line treatment of patients with unresectable or metastatic biliary tract cancer